首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Public Submissions on the Uganda National Biotechnology and Biosafety Bill, 2012 Reveal Potential Way Forward for Uganda Legislators to Pass the Bill
【24h】

Public Submissions on the Uganda National Biotechnology and Biosafety Bill, 2012 Reveal Potential Way Forward for Uganda Legislators to Pass the Bill

机译:关于2012年《乌干达国家生物技术和生物安全法案》的公开意见揭示了乌干达立法者通过该法案的潜在方法

获取原文
           

摘要

The Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an internationally binding instrument addressing issues of biosafety. Biosafety refers to the need to protect human health and the environment from the possible adverse effects of the products of modern biotechnology. Accordingly all countries to the convention are required to put in place regulatory mechanisms to enhance the safety of biotechnology in the context of the Convention’s overall goal of reducing all potential threats to biological diversity, while taking into account the risks to human health. Therefore each country party to the convention has its own procedures to enact laws to guide the safe use of biotechnology. In Uganda the process involves the drafting of the bill by the first parliamentary counsel, approval by cabinet, first reading at the parliament, committal to the responsible parliamentary sessional committee, tabling of the bill for public hearing, consultations, and final approval. In Uganda, the Committee on Science and Technology is responsible for the Biosafety Bill. In March 2013, the Committee tabled the bill for public hearing and submissions from public institutions. There were comments supporting the passage of the Bill and comments in objection.The reasons for objection are mainly due to precaution, speculation, lack of knowledge about biotechnology and biosafety, and alleged influence from biosafety entrepreneurs. This article reviews these public views, revealing controversy and possible consensus to pass the bill.
机译:《生物多样性公约》的《卡塔赫纳生物安全议定书》是解决生物安全问题的具有国际约束力的文书。生物安全性是指保护人类健康和环境免受现代生物技术产品可能产生的不利影响的需要。因此,在公约的总体目标是减少对生物多样性的所有潜在威胁的同时,考虑到人类健康的风险,要求公约的所有国家建立监管机制,以增强生物技术的安全性。因此,公约的每个缔约国都有自己的程序来制定法律,以指导生物技术的安全使用。在乌干达,此过程包括由第一位国会议员起草该法案,获得内阁批准,在国会进行一读,提交给负责的国会会议委员会,将该法案提交公众听证会,进行磋商和最终批准。在乌干达,科学技术委员会负责《生物安全法案》。 2013年3月,委员会将该法案提交公众听证会和公共机构的意见书。有反对该法案通过的评论和反对意见。反对的原因主要是由于预防措施,推测,对生物技术和生物安全的了解不足以及受到生物安全企业家的影响。本文回顾了这些公众观点,揭示了通过该法案的争议和可能达成的共识。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号